Navigation Links
Luminex® 200 xPONENT System from Upstate

ProductsLuminex® 200 xPONENT System from Upstate
Company Upstate
Item Luminex® 200 xPONENT System
Price $60,500.00
Description The Luminex® 200 System with the xPONENT Software Interface is ideal for developing single and multi-analyte assays using Upstate's Beadlyte® reagents. This system contains the new, powerful user friendly xPONENT software developed by Luminex. The user can design specific templates for commercial or home-made multiplex kits. The system has fully integrated graphing and data regression capabilities; the internal trouble shooting and self diagnostic capabilities allows the user to quickly identify problems.
Info UpstateUpstate
28820 Single Oak Drive
Temecula, CA 92590
Customer Service: 800-437-7500 or 951-676-8080
Tech Support: 800 548-7853
Fax Number: 800-437-7502 or 951-676-9209
Web Site: http://www.upstate.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Luminex® 200 IS System from Upstate
2. R.A.P.I.D. System from Idaho Technology Inc.
3. CEQ 8800 Genetic Analysis System from Beckman Coulter
4. ProteomeLab PA 800 Protein Characterization System from Beckman Coulter
5. ProteomeLab PF 2D Protein Fractionation System from Beckman Coulter
6. pET GST Fusion System 42 plus Competent Cells from Novagen
7. pET GST Fusion System 42 from Novagen
8. pET GST Fusion System 41 plus Competent Cells from Novagen
9. pET GST Fusion System 41 from Novagen
10. Mouse Dopaminergic Neuron Differentiation Kit, 2nd Generation from R&D Systems
11. CEQ 8000 Genetic Analysis System from Beckman Coulter
...
... Gene expression profiling allows a high-throuput ... that naturally occuring or artifitially induced changes ... in that system can be detected, studied, ... a broad range of genes at a ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
RORgamma (S-14)...
Biology Products:
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... MINNETONKA, Minn. , March 17, 2015 /PRNewswire/ ... sciences technology company specializing in clinical study management ... will be in attendance at ARENA,s Outsourcing in ... Cary, NC.  This event provides an excellent forum ... company,s easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... -- Reseachers at The Ohio State University have ... an effective method for preserving the important genetic diversity ... geranium, are some of the most popular flowers the ... Society listed more than 3,000 varieties of geranium in ...
... -- Two common dietary molecules found in legumes ... effects of radiation, researchers from the University of ... both human skin cells and a skin cancer-prone ... the damaging radiation found in sunlight, the team ...
... scientists today announced the results of a systematic effort ... worlds leading cause of cancer deaths. Appearing in the ... the research provides a comprehensive view of the abnormal ... 50 genomic regions that are frequently gained or lost ...
Cached Biology News:'TRAP' preserves genetic properties of popular geranium 2Antioxidants could provide all-purpose radiation protection 2Antioxidants could provide all-purpose radiation protection 3Genome study charts genetic landscape of lung cancer 2Genome study charts genetic landscape of lung cancer 3
(Date:4/16/2015)... and OSAKA, Japan ... Cell Research Application (CiRA) of Kyoto University and ... they will work together to develop clinical applications ... as heart failure, diabetes mellitus, neurological disorders and ... Cell Applications" (T-CiRA) is designed to expedite multiple ...
(Date:4/16/2015)... Irvine, CA (PRWEB) April 16, 2015 ... in the Buzz of BIO Contest for ... Industry Organization (BIO), the 2015 BIO International Convention will ... in Philadelphia, Pennsylvania. During the Buzz of BIO contest, ... like to see present at the conference. The community ...
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5